Gentamicin pharmacokinetics in neonates undergoing therapeutic hypothermia

Liana F. Mark, Addishiwot Solomon, Frances J. Northington, Carlton K.K. Lee

Research output: Contribution to journalArticle


OBJECTIVE:: To identify whether therapeutic hypothermia in newborns with hypoxic ischemic encephalopathy affects gentamicin pharmacokinetics. STUDY DESIGN:: Retrospective case-control study consisting of 16 neonates who underwent therapeutic hypothermia and received gentamicin with interpretable peak and trough serum levels obtained during the period of cooling and at steady state; comparator group consisting of 7 neonates met the criteria but did not undergo therapeutic hypothermia. RESULTS:: Significant differences in gentamicin pharmacokinetics were noted between the therapeutic hypothermia group and the comparator group in elimination rate constant (0.08/h versus 0.11/h; P < 0.01), elimination half-life (9.16 hours versus 6.56 hours; P < 0.01), and clearance (0.04 L/kg.h versus 0.05 L/kg.h; P < 0.01), respectively. Higher gentamicin trough serum concentrations were seen with the therapeutic hypothermia group (1.68 mcg/mL versus 0.77 mcg/mL; P < 0.01). CONCLUSIONS:: Therapeutic hypothermia is associated with alterations in gentamicin pharmacokinetics, reducing gentamicin clearance by 25.5% in neonates with hypoxic ischemic encephalopathy, which may result in increased trough serum concentrations.

Original languageEnglish (US)
Pages (from-to)217-222
Number of pages6
JournalTherapeutic Drug Monitoring
Issue number2
StatePublished - Apr 1 2013


  • aminoglycoside
  • cooling
  • hypoxic ischemic encephalopathy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Gentamicin pharmacokinetics in neonates undergoing therapeutic hypothermia'. Together they form a unique fingerprint.

  • Cite this